N-(N-tert-butoxycarbonyl-alanyl)-glycine | 26061-03-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(N-tert-butoxycarbonyl-alanyl)-glycine
• 英文别名: N-(N-tert-Butoxycarbonyl-alanyl)-glycin；N-tert-Butoxycarbonyl-DL-alanyl=>glycin；tert-Butyloxycarbonylalanylglycin；Boc-ala-gly-OH；2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]acetic acid
• CAS: 26061-03-0
• 化学式: C₁₀H₁₈N₂O₅
• mdl: MFCD00443512
• 分子量: 246.263
• InChiKey: PBGVVLQMNSPMKN-UHFFFAOYSA-N

物化性质

• 沸点：
  484.4±30.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(N-tert-butoxycarbonyl-alanyl)-glycine 、 N-(6-chloro-2-methoxy-acridin-9-yl)-N'-[3-(6-chloro-2-methoxyacridin-9-ylamino)-propyl]-propane-1,3-diamine 在 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl N-[1-[[2-[bis[3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]carbamate
  参考文献：
  名称：

  Antimalarial, Antitrypanosomal, and Antileishmanial Activities and Cytotoxicity of Bis(9-amino-6-chloro-2-methoxyacridines):  Influence of the Linker

  摘要：

  Forty bis(9-amino-6-chloro-2-methoxyacridines), in which acridine moieties are joined by alkanediamines, polyamines, or polyamines substituted by a side chain, were synthesized and tested for their in vitro activity upon the erythrocytic stage of Plasmodium falciparum, trypomastigote stage of Trypanosoma brucei, and amastigote stage of Trypanosoma cruzi and Leishmania infantum as well as for their cytotoxic effects upon MRC-5 cells. Results clearly showed the importance of the nature of the linker and of its side chain for antiparasitic activity, cytotoxicity, and cellular localization. Among several compounds devoid of cytotoxic effects at 25 mu M upon MRC-5 cells, one displayed IC50 values ranging from 8 to 18 nM against different P. falciparum strains while three others totally inhibited T. brucei at 1.56 mu M.

  DOI：

  10.1021/jm990946n
• 作为产物：
  描述：

  N-t-butyloxycarbonyl-alanine-N'-hydroxysuccinimide ester 在 sodium hydroxide 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 生成 N-(N-tert-butoxycarbonyl-alanyl)-glycine
  参考文献：
  名称：

  Miroshnikov,A.I. et al., Journal of general chemistry of the USSR, 1970, vol. 40, # 1, p. 202 - 213

  摘要：

  DOI：

文献信息

• Electrochemical Dimethyl <scp>Sulfide‐Mediated</scp> Esterification of Amino Acids
  作者：Yongli Li、Huamin Wang、Heng Zhang、Aiwen Lei

  DOI：10.1002/cjoc.202100395

  日期：2021.11

  for esterification of amino acids has been reported. A series of amino acids could react smoothly with alcohols, affording the desired esterification products with good efficiency. Importantly, the tolerance of peptides and gram-scale synthesis shed light on the utility of this protocol. Mechanistically, the dimethyl sulfide as a mediator plays an essential role in the transformation of amino acids

  已经报道了用于氨基酸酯化的二甲基硫醚介导的电化学合成策略。一系列氨基酸可以与醇类顺利反应，高效地提供所需的酯化产物。重要的是，肽的耐受性和克级合成阐明了该协议的实用性。从机制上讲，二甲基硫醚作为介体在氨基酸的转化中起着至关重要的作用。
• RILUZOLE PRODRUGS AND THEIR USE
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US20180036290A1

  公开（公告）日：2018-02-08

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的制药组合物包括替代利鲁唑前药，通过释放利鲁唑治疗包括黑色素瘤、乳腺癌、脑癌和前列腺癌等癌症。利鲁唑的前药具有增强的肝代谢稳定性，并通过口服途径输送到全身循环中，然后通过酶促或一般的生物物理释放过程在血浆中裂解释放利鲁唑。
• MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES
  申请人：Saulnier Mark G.

  公开号：US20130281657A1

  公开（公告）日：2013-10-24

  The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.

  本发明提供了制备大环化合物的方法，包括稳定大环化肽（MSPs）。根据适当取代的2-氨基噻唑-5-基甲醇生成的亚胺喹啉甲烷型中间体的亲核捕获，制备大环和MSP。在大环的情况下，首选亲核试剂可以从富电子芳香基团中选择，在MSP的情况下，至少有一种氨基酸包含富电子芳香基团。此外，该概念可以扩展到取代噻唑的其他相关5-成员杂环系统，例如咪唑或噁唑。生成相应的亚胺喹啉甲烷型中间体的条件可能与用于2-氨基噻唑-5-基甲醇的条件相似或不同。
• PHARMACEUTICAL COMPOSITIONS COMPRISING RILUZOLE PRODRUGS
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：EP4011870A1

  公开（公告）日：2022-06-15

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。
• Prodrugs of riluzole and their method of use
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US10639298B2

  公开（公告）日：2020-05-05

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。